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A B S T R A C T
Background: Late gadolinium enhancement (LGE) is a standard method to evaluate myocardial ﬁbrosis,
but restricted due to contrast agent contraindications. Non-contrast T1rho can generate endogenous
contrast, and detect ﬁbrosis in chronic myocardial infarction. However, T1rho for hypertrophic
cardiomyopathy (HCM) patients is still unreported. The present study aimed to investigate T1rho for
ﬁbrotic assessment and the clinical implication in HCM patients.
Methods: 18 HCM patients and 8 controls underwent T1rho, cine, and LGE cardiac magnetic resonance
(CMR). T1rho relaxation time maps were created. Left ventricular (LV) parameters assessed included
wall thickness, wall thickening, chamber volumes, ejection function, and ﬁbrotic size. New York Heart
Association (NYHA) functional classiﬁcation was conducted.
Results: Hyper-T1rho value was identiﬁed in 12 HCM patients, consistent with LGE. The mean T1rho
values of controls, LGE-negative patients, and remote myocardium of LGE-positive patients were
42.2  1.6 ms, 43.9  2.5 ms, and 42.5  1.2 ms respectively, and these values showed no signiﬁcant
difference (all p > 0.05). T1rho-3-SD and T1rho-4-SD ﬁbrotic sizes (32.5  14.0% and 25.1  11.5%) did not
differ from LGE ﬁbrotic size (28.1  11.2%) (both p > 0.05). For the ﬁbrotic size, T1rho-3-SD method obtained
the strongest correlation with LGE (r = 0.88, p < 0.001), and T1rho-4-SD obtained the minimal mean
difference with LGE (3.1%; 15.2 to 9.1%), compared with other SDs. All the ﬁbrotic sizes assessed by both
methods correlated directly with LV maximal end-diastolic thickness (all p < 0.05). Negative correlation was
found between T1rho-4-SD ﬁbrotic size and LV ejection fraction (r = 0.49, p = 0.11). T1rho-4-SD ﬁbrotic size
showed positive correlation with NYHA class (r = 0.46, p = 0.13).
Conclusions: T1rho CMR has potential to detect ﬁbrosis in HCM patients. 4-SD may be the appropriate
threshold for assessment.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Hypertrophic cardiomyopathy (HCM) is a primary myocardial
disease with highly heterogeneous clinical presentations ranging
from asymptomatic to severe symptomatic expressions. HCM
patients suffer from diastolic and systolic dysfunctions [1–4]
possibly due to myocardial hypertrophy, myocardial ﬁber disarray,* Corresponding author at: No. 37, Guoxuexiang, Chengdu 610041, Sichuan,
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsmyocardial ﬁbrosis, and small vessel disease [5–7]. HCM is a
leading cause of sudden cardiac death in young individuals,
including athletes [8,9]. Thus, efﬁcient techniques for diagnosis
and risk stratiﬁcation for HCM are indeed needed. Cardiac
magnetic resonance (CMR) provides morphological and functional
information with satisfactory temporal and spatial resolution. Late
gadolinium enhancement (LGE) can provide abundant information
about myocardial ﬁbrosis in HCM patients [10], which is
considered to have signiﬁcant value in cardiac remodeling and
prognosis. Moreover, LGE volume or extent is associated with left
ventricular (LV) systolic function and impaired New York Heart
Association (NYHA) functional class [11,12]. reserved.
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the challenge remains in patients with contrast agent contra-
indications. T1rho CMR with endogenous contrast may overcome
the limitations of contrast-enhanced approaches [13]. This emerg-
ing and innovative technique has been used to study articular
cartilage [14], intervertebral disc [15], brain [16], and liver [17], but
less in heart [18]. Hyper-intensity in the myocardial T1rho map
was observed in LGE areas of swine chronic myocardial infarction
(MI) model [13]. However, to our best knowledge, T1rho imaging
for HCM patients is still unreported. In the present study, we made
an effort to evaluate whether T1rho CMR is able to assess ﬁbrosis,
and predict ventricular function and NYHA class in a subgroup of
HCM patients.
Materials and methods
Patients
This prospective study included 18 patients diagnosed with
HCM between December 2012 and April 2014. The deﬁnition of
HCM was based on the World Health Organization/International
Society and Federation of Cardiology criteria [19]. NYHA classiﬁ-
cation was evaluated independently by two experienced cardiol-
ogists. In addition, eight subjects without cardiovascular disease
history were recruited as healthy controls. The study protocol was
approved by the local human study committee after obtaining
written informed consent from each participant.
CMR protocol
CMR was performed on a 3.0 Tesla magnetic resonance imaging
(MRI) system (Magnetom Trio, Siemens Medical Systems, Erlan-
gen, Germany) with a commercially available cardiac surface coil.
The T1rho images were obtained using an electrocardiogram
(ECG)-gated T1rho prepared gradient echo sequence in three
short-axis slices from the base to the apex. This T1rho sequence
was previously reported to be able to reduce B0 and B1 ﬁeld
inhomogeneities [20]. Each slice can obtain three T1rho images
with different time of spin locking (TSL) in a segmented fashion
within a single breath-hold. Imaging parameters were: repetition
time (TR) 3.2 ms, echo time (TE) 1.52 ms, ﬂip angle 158, bandwidth
606 Hz/Px, ﬁeld-of-view (FOV) 172 mm  232 mm, voxel size
1.8 mm  1.8 mm  8.0 mm, locking ﬁeld B1 8uT, TSL 10, 30,
50 ms, and spin locking frequency (SLF) 340.6 Hz. Larger SLF was
restricted by the speciﬁc absorption rate (SAR) limit imposed on
the CMR system.
Cine CMR sequence was then performed in the 4-chamber, 3-
chamber, 2-chamber and short-axis views from the base to theFig. 1. Wall thickening of left ventricular (LV) maximal end-diastolic wall thickness (EDT
thickness (ESTH) of the same site (arrowed line in the right panel) were used to calculate
formula: (ESTH–EDTH)/EDTH  100%. ED, cine image at end-diastole; ES, cine image aapex. Short-axis images of 12–14 sections were obtained using a
steady-state free precession with retrospective ECG triggering.
Image parameters were: TR 3.0 ms, TE 1.5 ms, ﬂip angle 508,
bandwidth 977 Hz/Px, FOV 172 mm  227 mm, and voxel size
1.3 mm  1.3 mm  8.0 mm.
LGE images were obtained 10–15 min after a bolus adminis-
tration of gadolinium-DTPA (0.15 mmol/kg, Magnevist, Bayer
Health Care Pharmaceuticals, Leverkusen, Germany) using an
ECG-gated breath-hold inversion recovery Turbo FLASH in short-
axis and long-axis slices. The infusion rate of contrast agent was
3 ml/min, followed by the saline ﬂush (2–3 ml more than volumes
of Magnevist) with the same injection rate. Imaging parameters
were: TR 6.5 ms, TE 3.55 ms, inversion time 300–360 ms (depend-
ing on patients’ heart rates), ﬂip angle 208, bandwidth 287 Hz/Px,
FOV 172 mm  232 mm, voxel size 1.8 mm  1.4 mm  8.0 mm.
Image analysis
The CMR data were reviewed independently by two experi-
enced cardiac radiologists blind to the clinical parameters. LV
mass, chamber volume, and function were analyzed in the cine
short-axial images with the Argus software (Siemens Medical
Systems, Erlangen, Germany). LV maximal end-diastolic wall
thickness (EDTH) and end-systolic wall thickness (ESTH) of the
same site were manually measured with syngo-fV (Siemens
Medical Systems) (Fig. 1). The wall thickening of LV maximal EDTH
was computed: (ESTH–EDTH)/EDTH x 100%. The T1rho relaxation
time maps were created by a custom-made software written in
Matlab 7.1 (The Mathworks, Natick, MA, USA). The remote area of
HCM patients was deﬁned visually as a region of myocardium
without LGE. The mean relaxation time and SD of controls or
remote area were determined by drawing a region of interest (ROI,
at least 50 pixels) in normal or remote myocardium each slice with
ImageJ (NIMH, NIH, Bethesda, MD, USA). Fibrotic size was traced
manually and quantiﬁed with ImageJ using 3 slices (from the base
to the apex) LGE images or T1rho relaxation time maps before
being multiplied by 1.05 g/cm3 [1] (expressed in gram). LGE for
ﬁbrotic size was performed visually, while T1rho for ﬁbrotic size
using threshold technique with 2 SDs, 3 SDs, 4 SDs, 5 SDs, and 6 SDs
above the mean T1rho value of the remote myocardium. The
percent ﬁbrotic size was expressed as a percentage of the total 3-
slice mass (g): (Mﬁbrotic/Mtotal)  100%, with ﬁbrotic mass (Mﬁbrotic)
and total 3-slice mass (Mtotal).
Statistical analysis
All the data are expressed as mean  SD, unless stated otherwise.
Comparison of continuous variables was conducted with the one-wayH). EDTH of LV maximal wall (arrowed line in the left panel) and end-systolic wall
 the wall thickening. The wall thickening of LV maximal EDTH was computed by the
t end-systole.
Table 1
Characteristics of HCM patients and controls.
HCM (n = 18) Control (n = 8) p
Age (y) 52  14 43  10 0.12
Females 9 [50] 5 [63] 0.56
Dyspnea 2 [11] –
Syncope 6 [33] –
NYHA (I/II/III/IV) 8/4/4/2 –
LV mass (g) 151.2  35.7 89.0  20.7 <0.001
LVEDV (ml) 135.0  42.9 142.9  25.5 0.64
LVESV (ml) 59.4  41.3 52.4  8.4 0.64
LVSV (ml) 75.9  19.4 90.5  18.9 0.09
LVEF (%) 58.3  13.1 63.1  3.5 0.33
LV maximal EDTH
(mm)
23.6  5.1 8.3  1.0 <0.001
Wall thickening of
LV maximal EDTH (%)
24.2  16.8 77.5  23.5 <0.001
Data are presented as mean  SD or n [%]. HCM, hypertrophic cardiomyopathy;
NYHA, New York Heart Association; LV, left ventricular; LVEDV, LV end-diastolic
volume; LVESV, LV end-systolic volume; LVSV, LV stroke volume; LVEF, LV ejection
fraction; EDTH, end-diastolic wall thickness.
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analysis. Relationships between variables were determined by
Pearson correlation. All the comparisons and correlations were
two-tailed, and a p < 0.05 was considered to be statistically
signiﬁcant. Above data processing and statistical analyses were
performed using the SPSS V.13.0 statistical program (SPSS Inc.,
Chicago, IL, USA). Limits of agreement for ﬁbrotic sizes between LGE
and T1rho CMR were determined by Bland–Altman analysis using
MedCalc V.11.4.2.0 (MedCalc Software bvba, Ostend, Belgium).Fig. 2. T1rho relaxation time mapping in a late gadolinium enhancement (LGE)-positive p
hyper-T1rho area (red arrow in A2) and LGE area (red arrow in A1), whereas no hyper-T1r
C1). (A1, B1, and C1) LGE images of the patients and control. (A2, B2, and C2) T1rho reResults
Characteristics of patients
A total of 18 HCM patients and 8 controls were included in the
analysis, and the characteristics are presented in Table 1. There
were no signiﬁcant differences in age and gender between patients
and controls (all p > 0.05). Mean age of patients was 52  14 years
(range: 25–71 years), and nine (50%) were females. The average LV
mass of patients was 151.2  35.7 g (range: 91.4–220.2 g), and
obviously greater than that of controls (89.0  20.7 g, p < 0.001). LV
maximal EDTH in patients (23.6  5.1 mm) was signiﬁcantly greater
than controls (8.3  1.0 mm; p < 0.001). Furthermore, HCM patients
showed worse wall thickening at LV maximal wall (24.2  16.8% vs.
77.5  23.5%, p < 0.001). There were no signiﬁcant differences in LV
chamber volumes and function (all p > 0.05). NYHA classes by clinical
symptoms were class I in eight patients, class II in four patients, class
III in four patients, and class IV in two patients.
Fibrotic size
Hyper-T1rho value was identiﬁed in 12 HCM patients,
consistent with LGE. The mean T1rho values of controls, LGE-
negative patients, and remote myocardium of LGE-positive
patients were 42.2  1.6 ms, 43.9  2.5 ms, and 42.5  1.2 ms
respectively, and these values showed no signiﬁcant differences
(all p > 0.05). Fig. 2 shows the location of hyper-T1rho value was in
concordance with LGE, and no hyper-T1rho value was observed in the
LGE-negative patient and control. With visual measurement, the
mean ﬁbrotic size calculated by LGE imaging was 28.1  11.2%atient, LGE-negative patient, and control. There was spatial correspondence between
ho relaxation times (B2, C2) were found in the LGE-negative patient and control (B1,
laxation time maps of the patients and control.
Fig. 3. Comparisons, correlations, and Bland–Altman plots of ﬁbrotic sizes determined by T1rho (3-SD and 4-SD) and late gadolinium enhancement (LGE). The upper three
panels show the nonsigniﬁcant difference (left), signiﬁcant correlation (middle), and minor mean difference between T1rho (3-SD) and LGE ﬁbrotic sizes. The lower three
panels show the nonsigniﬁcant difference (left), signiﬁcant correlation (middle), and minor mean difference between T1rho (4-SD) and LGE ﬁbrotic sizes.
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assessed by T1rho imaging were 41.2  17.4% at 2 SDs, 32.5  14.0%
at 3 SDs, 25.1  11.5% at 4 SDs, 19.3  9.6% at 5 SDs, and 15.2  8.3% at
6 SDs. Fibrotic sizes determined by T1rho-3-SD and T1rho-4-SD
methods showed no differences from that calculated by LGE (T1rho-3-
SD vs. LGE: p = 0.41; T1rho-4-SD vs. LGE: p = 0.52; Fig. 3). However,
ﬁbrotic size obtained by LGE imaging differed from those computed by
T1rho imaging at 2 SDs (p = 0.04), 5 SDs (p = 0.05), and 6 SDs (p = 0.004).
All ﬁbrotic sizes determined using T1rho method correlated signiﬁ-
cantly with that determined by LGE. However, the T1rho-3-SD method
obtained the strongest correlation (r = 0.88, p < 0.001; Fig. 3), com-
pared with the T1rho-2-SD (r = 0.84, p = 0.001), T1rho-4-SD (r = 0.85,
p < 0.001; Fig. 3), T1rho-5-SD (r = 0.847, p = 0.001), and T1rho-6-SD
(r = 0.81, p = 0.002). Bland–Altman analysis revealed that T1rho-4-SD
method obtained the minimal mean difference with LGE (3.1%; 15.2
to 9.1%; Fig. 3), compared with T1rho-2-SD (13.1%; 6.9 to 33%), T1rho-
3-SD (4.3%; 8.8 to 17.4%; Fig. 3), T1rho-5-SD (8.8%; 20.5 to 2.9%),
and T1rho-6-SD (12.9%; 26 to 0.1%).Table 2
Relationships between ﬁbrotic sizes (T1rho and LGE methods) and LV other parameter
T1rho-2-SD T1rho-3-SD 
LV mass 0.38, 0.28 0.36, 0.31 
LV maximal EDTH 0.75, 0.02 0.8, 0.01 
Wall thickening of LV maximal EDTH 0.44, 0.24 0.49, 0.18 
LVSV 0.21, 0.52 0.25, 0.44 
LVEF 0.42, 0.18 0.38, 0.22 
NYHA class 0.26, 0.42 0.28, 0.38 
Data are presented as r, p. LGE, late gadolinium enhancement; LV, left ventricular; NYHA
volume; LVEF, LV ejection fraction.Fibrotic size, wall thickness, and cardiac function
Correlations between ﬁbrotic sizes and LV other parameters
and NYHA class are summarized in Table 2. The ﬁbrotic sizes
computed by LGE and T1rho methods (all the ﬁve SDs) correlated
positively with LV maximal EDTH (LGE: r = 0.8, p = 0.01; T1rho-2-
SD: r = 0.75, p = 0.02; T1rho-3-SD: r = 0.8, p = 0.01; T1rho-4-SD:
r = 0.89, 0.001; T1rho-5-SD: r =0.91, p = 0.001; T1rho-6-SD:
r = 0.88, p = 0.002; Table 2 and Fig. 4). Nevertheless, no signiﬁcant
correlations were observed between ﬁbrotic sizes and LV mass,
wall thickening of LV maximal EDTH, LV chamber volumes, LV
stroke volume (LVSV), LV ejection fraction (LVEF), or NYHA class,
except for the inverse correlation between T1rho-6-SD ﬁbrotic size
and NYHA class (p < 0.05). However, for T1rho-4-SD ﬁbrotic size,
which is not signiﬁcantly different from LGE ﬁbrotic size, there
were high r and low p values in LVSV (r = 0.43, p = 0.16), LVEF
(r = 0.49, p = 0.11), NYHA class (r = 0.46, p = 0.13), and wall
thickening of LV maximal EDTH (r = 0.52, p = 0.15).s and NYHA class.
T1rho-4-SD T1rho-5-SD T1rho-6-SD LGE
0.32, 0.36 0.29, 0.42 0.23, 0.52 0.12, 0.75
0.89, 0.001 0.91, 0.001 0.88, 0.002 0.8, 0.01
0.52, 0.15 0.55, 0.13 0.53, 0.15 0.61, 0.08
0.43, 0.16 0.48, 0.11 0.55, 0.07 0.16, 0.63
0.49, 0.11 0.48, 0.12 0.51, 0.09 0.06, 0.86
0.46, 0.13 0.53, 0.08 0.61, 0.04 0.30, 0.34
, New York Heart Association; EDTH, end-diastolic wall thickness; LVSV, LV stroke
Fig. 4. Correlations between left ventricular (LV) maximal end-diastolic wall thickness (EDTH) and ﬁbrotic sizes with late gadolinium enhancement (LGE), T1rho-3-SD, and
T1rho-4-SD methods. Left panel shows LV maximal EDTH related positively to LGE ﬁbrotic size. Middle panel shows the positive correlation between LV maximal EDTH and
T1rho-3-SD ﬁbrotic size. Right panel shows LV maximal EDTH was directly associated with T1rho-3-SD ﬁbrotic size.
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HCM is an idiopathic disease with pathological myocardial
ﬁbrosis, which is considered to be associated with ventricular
arrhythmias and dysfunction [2,5,21]. To detect myocardial
ﬁbrosis, LGE was clinically validated and widely studied in HCM
[22]. However, LGE is not able to be applied in patients with
contrast agent contraindications. To the best of our knowledge,
endogenous contrast T1rho method has not previously been used
in assessment of ﬁbrosis in HCM patients.
Our preliminary data showed that ﬁbrotic sizes determined by
T1rho CMR at 3-SD and 4-SD did not signiﬁcantly differ from and
associated strongly with that determined by LGE CMR. Addition-
ally, 3-SD and 4-SD T1rho methods showed minor mean
differences with LGE. Witschey et al. [13] reported an agreement
in infarct sizes between T1rho and LGE methods in a porcine model
of chronic MI. The mechanism of LGE involves the difference of
contrast agent washout between remote myocardium and ﬁbrosis
[23]. LGE in HCM is likely to occur in replacement ﬁbrosis including
increased collagen concentration [7,24,25]. T1rho endogenous
contrast involves different water proton interactions, including
chemical exchange, dipole–dipole coupling, and diffusion
[13]. Moreover, elevated T1rho relaxation time is most likely to
imply granulation and scar tissue in myocardial infarction model
[18]. Taken together, T1rho and LGE can detect replacement
ﬁbrosis in chronic phase, suggesting the right threshold for ﬁbrotic
size calculated by T1rho may be the SD which is in strongest
accordance with LGE. Thus, hyper-T1rho value can be deﬁned as
the value greater than this SD above mean value of remote
myocardium. Given the overestimated infarct size by LGE and
T1rho compared with histology [13], in present study, 4-SD may be
the appropriate threshold.
The current study showed ﬁbrotic sizes calculated by both LGE
and T1rho methods were associated with LV maximal EDTH,
conﬁrming previous investigation that scarring extent correlated
with EDTH [1]. Myocardial ﬁbrosis is possibly considered as a long-
term result of microvascular ischemia, ultimately leading to
systolic abnormality in HCM, conﬁrmed by the inverse correlation
between ﬁbrotic extent and LVEF [11,26–28]. However, our study
found negative correlation (but not signiﬁcant) between LVEF and
T1rho-4-SD ﬁbrotic size. In clinical respect, the presence of
myocardial ﬁbrosis in HCM is modestly associated with heart
failure symptoms, and correlation between myocardial ﬁbrosis
and NYHA class has been found [12,27], suggesting ﬁbrotic size
may be a predictor of NYHA class. However, our results showed a
negative correlation with nonsigniﬁcance between T1rho-4-SD
ﬁbrotic size and NYHA class. Moreover, there is a study whichincluded a relatively small population, showing no correlation
between ﬁbrotic extent and LVEF or NYHA class [2]. Thus,
nonsigniﬁcant correlation between ﬁbrotic size and LV function
and NYHA class may be contributed by small sample or different
spectrum of HCM patients.
Longitudinal rotating-frame relaxation time T1rho is contrib-
uted by magnetic ﬁeld ﬂuctuation because of on-off binding water
molecules [29]. T1rho tissue properties become similar to T2 tissue
contrast as B1 is at a certain value [30], which may be explained by
the interactions of water protons. The interactions of macromo-
lecular water include dipole–dipole coupling, chemical exchange,
and diffusion. However, the dominant T1rho relaxation mecha-
nism is still unknown [13,31]. Myocardial scar was found to cause
T1rho relaxation alteration compared with healthy myocardium
[31]. Musthafa et al. [18] found T1rho relaxation times were
elevated nonsigniﬁcantly at day 3 and further increased signiﬁ-
cantly at days 7 and 14, indicating the hyper-T1rho value possibly
represents the ﬁbrosis in chronic phase, corresponding to the study
of Witschey et al. [31]. However, T1rho value increased immedi-
ately after cerebral infarction in rat models [32]. Additionally,
T1rho correlated directly to proteoglycan content in intervertebral
discs, whereas it was related inversely to that in articular cartilage,
suggesting that the relative composition in different tissue affects
T1rho [33]. The above studies indicate T1rho alteration, including
value and time course, may differ in different tissue due to various
composition or relative composition. Nevertheless, abnormal
T1rho relaxation time was associated with granulation or scar
tissue by histology in swine and rat MI models [13,18], suggesting
T1rho methods may augment or even replace LGE CMR.
Van Oorschot et al. [34] reviewed several types of CMR
techniques. Compared with LGE, T1rho CMR without contrast
agent may assess the ﬁbrotic size and is free of anaphylactic
reactions and nephrogenic systemic ﬁbrosis (NSF). Extracellular
volume (ECV) mapping is excellent for diffuse ﬁbrosis. But ECV
method needs dozens of minutes for contrast equilibrium and
involves acquirement of pre- and post-contrast maps as well as
hematocrit value [35,36]. T1rho method is simple and time-saving,
with no need for gadolinium agent, acquisition of two different-
time maps, or patients’ blood in comparison with ECV mapping.
Native T1 mapping for diffuse ﬁbrosis is also independent of renal
function due to no need for contrast agent. However, change is very
small between ﬁbrosis and remote myocardium [37]. T1rho
relaxation times have a wider range of values compared with T1
relaxation, and seem to associate earlier and better with
therapeutic response and disease progression [38].
There were several limitations to this study. Firstly, the sample
size was relatively small, but our data have highlighted a
C. Wang et al. / Journal of Cardiology 66 (2015) 520–526 525promising method for patients with contrast agent contraindica-
tions. Secondly, there were no pathologic data to support one SD
threshold for ﬁbrotic size. However, we analyzed the agreement
between T1rho threshold and LGE visual methods for ﬁbrotic sizes
despite the different contrast mechanisms. Finally, 340 Hz was the
largest spin-locking frequency we could use with the limitation of
SAR imposed by the MRI system and limited breath-holding time
despite 500 Hz being commonly selected [13,17]. It is necessary for
a further larger cohort study with modiﬁed T1rho technique.
In conclusion, ﬁbrotic size assessed by T1rho CMR at 4-SD was
in good agreement with LGE, and associated with LV maximal
EDTH. 4-SD may be the right threshold for ﬁbrotic assessment
using T1rho method. Overall, the non-contrast T1rho CMR is
promising to detect ﬁbrosis in HCM patients and provides an
option for HCM patients with contrast agent contraindications.
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